Back to Media center

Media Releases

Select year

Sort by

88 items found

FDA Selects Kyowa Kirin for Precheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience

June 30, 2026

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH

Kura Oncology and Kyowa Kirin report encouraging long-term results for ziftomenib / 7+3 combination in newly diagnosed AML

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

FDA Approves New Dosing Option for CRYSVITA^® (burosumab-twza) in Adults With XLH

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

CRYSVITA^® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Showing 88 - 1 of 9